Data / Drug companies / Risperidone

Risperidone: 43 companies and 194 products in the FDA NDC directory

Risperidone is listed in the FDA National Drug Code Directory by 43 companies, with 194 products in commercial distribution. 167 of the products (86.1%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, film coated; tablet, orally disintegrating, and the newest product started marketing on August 6, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it

43

Products

194

Generic (ANDA) products

167 (86.1%)

Application numbers

28

Routes

Oral, Subcutaneous, Intramuscular

Brand names

Uzedy, Risperdal, Risperdal M-Tab, Risperdal Consta, Rykindo Extended-Release Microspheres

openFDA record search

api.fda.gov

Companies that list risperidone

Ranked by number of products. Finished drugs in commercial distribution.

Dosage forms

Marketing categories

Pharmacologic classes

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.